Amylyx Pharmaceuticals (AMLX) Total Liabilities (2021 - 2026)

Amylyx Pharmaceuticals has reported Total Liabilities for 6 years, with the latest figure at $25.4 million in Q2 2026.

• On a quarterly basis, Total Liabilities fell 4.95% year-over-year to $25.4 million in Q2 2026; TTM through Jun 2026 was $25.4 million, a 4.95% decrease from a year earlier, with the FY2025 full-year figure at $27.4 million, down 5.14% from the prior year.
• Total Liabilities was $25.4 million for Q2 2026 at Amylyx Pharmaceuticals, up from $20.4 million in the prior quarter.
• The five-year high for Total Liabilities was $93.0 million in Q1 2024, with the low at $18.3 million in Q1 2025.
• Average Total Liabilities over 5 years is $44.7 million, with a median of $35.5 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 191.7% in 2022, then slumped 80.37% in 2025.
• Over 5 years, Total Liabilities stood at $50.8 million in 2022, then soared by 65.25% to $84.0 million in 2023, then slumped by 65.64% to $28.9 million in 2024, then decreased by 5.14% to $27.4 million in 2025, then fell by 7.26% to $25.4 million in 2026.
• The last three Total Liabilities figures came in at $25.4 million (Q2 2026), $20.4 million (Q1 2026), and $27.4 million (Q4 2025), per Business Quant data.